Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guilong Dan is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. It is specifically indicated for the treatment of chronic prostatitis, particularly cases diagnosed with Qi stagnation and blood stasis patterns. The formulation typically incorporates herbal ingredients such as *Angelica sinensis* (Dang Gui) and *Lumbricus* (Di Long), which are traditionally used to promote blood circulation, resolve stasis, and clear heat and dampness. Clinical and pharmacological research conducted at the developing institution suggests that Guilong Dan exerts its therapeutic effects by improving prostatic microcirculation and inhibiting the production of pro-inflammatory cytokines, thereby alleviating pelvic pain and urinary dysfunction associated with chronic prostatic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guilong Dan.